Temporal Dynamics of Polyp Regression and Retreatment Burden in As-Needed VEGF Inhibitor Therapy: A 24-Month Study. (PubMed, Pharmaceuticals (Basel)) - Sep 27, 2026 - "All patients initially received three monthly intravitreal injections of either aflibercept (2 mg) or brolucizumab, followed by as-needed treatment for 24 months...In contrast, regression at 12 months-rather than at 3 months-was more strongly associated with fewer additional injections during the second year. The most recent status of the polypoidal lesion was associated with the number of additional injections during the corresponding 12-month period, suggesting that ICGA-based assessment may be important for predicting treatment responsiveness."
Journal • Age-related Macular Degeneration
|
|
Kenji Kashiwagi; Misa Kimura; Yoichi Sakurada; Yoshiko Fukuda; Yumi Kotoda
|